Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.
This study is is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. Accordingly, the investigators will evaluate the effect of NMN on how well the hormone insulin works to control blood sugar. The investigators will also look at the effects of NMN on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. Data from studies conducted in rodents have shown that NMN supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| NMN supplementation | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NMN supplement | Dietary Supplement | Intervention will last at least 8 weeks in the form of two capsules (250 mg total). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscle insulin sensitivity | The outcome will be assessed by hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period. | before and after at least 8 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in liver insulin sensitivity | The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period. | before and after at least 8 weeks of treatment |
| Change in adipose tissue insulin sensitivity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Samuel Klein, MD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33888596 | Derived | Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021 Jun 11;372(6547):1224-1229. doi: 10.1126/science.abe9985. Epub 2021 Apr 22. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| ID | Term |
|---|---|
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D009537 | Nicotinamide Mononucleotide |
| ID | Term |
|---|---|
| D012265 | Ribonucleotides |
| D009711 | Nucleotides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Intervention will last at least 8 weeks in the form of two capsules. |
|
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period. |
| before and after at least 8 weeks of treatment |
| Change in body fat mass | The outcome will be measured by using dual-energy X-ray absorptiometry before and after intervention period. | before and after at least 8 weeks of treatment |
| Change in fat free mass | The outcome will be measured by using dual-energy X-ray absorptiometry before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in intra-abdominal adipose tissue volume | The outcome will be measured by using magnetic resonance imaging before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in intrahepatic triglyceride content | The outcome will be measured by using magnetic resonance imaging before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in blood pressure | The outcome will be assessed by measuring blood pressure at rest before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in plasma glucose concentration | The outcome will be determined by plasma glucose concentration after overnight fasting, before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in fasting insulin | The outcome will be determined by plasma insulin concentration after overnight fasting, before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in fasting free fatty acid | The outcome will be determined by plasma free fatty acid concentration after overnight fasting, before and after intervention period. | before and after at least 8 weeks of treatment |
| Changes in tissue NAD content | The outcome will be assessed by measuring NAD content before and after intervention period | before and after at least 8 weeks of treatment |
| Changes in protein levels in skeletal muscle insulin signaling | The outcome will be determined by Western blot by using samples collected before and after intervention period | before and after at least 8 weeks of treatment |